SACT Pathways, Guidelines for the Management of SACT Induced Adverse Reactions and Nursing 

SACT Pathways 

• 24 Hour Telephone Advice Service  
• Bisphoshonate Guidelines incorporating prescribing in Renal Impairment v2
  
• Extravasation v5 (Funding arrangements for Savene are outstanding but are currently being addressed through Acute Trusts D&Ts)  
• Guidelines for the Management of SACT Induced Nausea and Vomiting v6
  
• Guidelines for Use of G-CSF in Adult Haematology and Oncology Patients v5
  
• Handling, Administration, Health and Safety 
  
• Hypercalcaemia Guidelines v3
  
• Intrathecal 
  
• Guidelines on the Safe Use of Oral Anti-Cancer Medicines 
  
• Neutropenic sepsis  (Please refer to individual Trust policies for the Antimicrobial Management of Neutropenia) 
  
• Preparation and Pharmacy 
  
• SACT Anaphylaxis
  
• SACT Induced Diarrhoea 
  
• SACT Induced Mucositis & Stomatitis 
  
• SACT Location of Delivery 
  
• Vascular Access Guidelines 

Guidelines for the Management of SACT Induced Adverse Reactions

• Guidelines for Bevacizumab induced hypertension v1 (Reviewed Nov 13)  
  
• Dose reductions and management of adverse events to Ceritinib v1 
  
• Guidelines for Cetuximab induced rashes v3 
  
• Ipilimumab-related toxicity Management of Diarrhoea v1
• Ipilimumab-related toxicity Management of Endocrinopathy v1
• Ipilimumab-related toxicity Management of Hepatotoxicity v1
• Ipilimumab-related toxicity Management of Neurological Reactions v1
• Ipilimumab-related toxicity Management of Skin Toxicities v1
• Guidelines for the Management of Immune-related toxicities with immunotherapy treatment v2
• Dose modification schedule & management of adverse reactions to Nintedanib (Vargatef®) v1    
• Guidance on the assessment and Management of Oxaliplatin induced Neuropathy v1
• Algorithm for continuation and discontinuation of Pertuzumab and Trastuzumab based on LVEF assessments (for use with BRE-032) v1 
  
• Dose modifications & management of adverse reactions to Regorafenib v1                         
  
• Management of symptomatic adverse reactions to Trastuzumab Emtansine (Kadcyla®) v1 
  
• Dose modification schedule & management of adverse reactions to Vandetanib v1 
  
• Dose modification schedule & management of adverse reactions to Vemurafenib v1 

Nursing 

Palliative Care Guidelines

• Palliative Care Guideline Plus Website

Training and Workforce

• Advanced SACT final module outline 2011 
  
• Arrangement for Cross-Trust working 
  
• Chemotherapy Workbook 1
• 2012 Chemotherapy Workbook 2 
  
• Nurse led Chemotherapy: Nurse led guidelines
• In House Education Training Assessment Tool V1.0